AnGes has filed a patent for a non-naturally occurring composition that includes a CRISPR nuclease with a sequence having at least 95% identity to SEQ ID NO: 1. The composition can also include a nucleic acid molecule encoding the CRISPR nuclease. GlobalData’s report on AnGes gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AnGes, NSAID cancer drugs was a key innovation area identified from patents. AnGes's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Patent filed for a non-naturally occurring crispr nuclease composition
A recently filed patent (Publication Number: US20230303989A1) describes a non-naturally occurring composition involving CRISPR technology. The composition includes a CRISPR nuclease with a specific amino acid sequence or a nucleic acid molecule encoding the CRISPR nuclease. Additionally, the composition may contain one or more RNA molecules or a DNA polynucleotide encoding these RNA molecules. These RNA molecules are designed to form a complex with the CRISPR nuclease and/or target the complex to a specific site.
The patent claims specify various aspects of the composition. For example, the CRISPR nuclease should have at least 90% identity to a specific amino acid sequence (SEQ ID NO: 1), and the RNA molecules can have sequences selected from a group of sequences (SEQ ID NOs: 4-36). Furthermore, the composition may include a transactivating CRISPR RNA (tracrRNA) molecule with specific sequences (SEQ ID NOs: 8-14, 17, 22-28, and 32).
The patent also describes the use of single-guide RNA (sgRNA) molecules, which consist of a guide sequence portion and a scaffold portion. The guide sequence portion can have sequences selected from the same group mentioned earlier (SEQ ID NOs: 4-36). The scaffold portion should be at least 79 nucleotides in length.
The patent further mentions the possibility of creating a nickase or a catalytically dead nuclease by introducing specific amino acid substitutions at certain positions in the CRISPR nuclease sequence.
The composition may also include a donor template molecule, and the RNA molecules can be formed through in vitro transcription (IVT) or solid-phase artificial oligonucleotide synthesis.
Overall, this patent application describes a non-naturally occurring composition involving CRISPR technology, specifically focusing on the CRISPR nuclease and its interaction with RNA molecules. The composition's design allows for targeted gene editing and manipulation, potentially opening up new possibilities in the field of genetic engineering.
To know more about GlobalData’s detailed insights on AnGes, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
